Revolution Medicines, Inc.
revolutionmedicines.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
18
Active
13
Phase 3
5
Total enrollment
8,315
Pipeline matrix
Showing 25 of 25 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| daraxonrasib | — | — | 7 | ||||
| RMC-6236 | — | — | — | 5 | |||
| Gemcitabine | — | — | — | — | 4 | ||
| nab-paclitaxel | — | — | — | — | 4 | ||
| Zoldonrasib | — | — | — | — | 2 | ||
| Oxaliplatin | — | — | — | — | — | 2 | |
| Leucovorin | — | — | — | — | — | 2 | |
| 5-Fluorouracil | — | — | — | — | — | 2 | |
| Irinotecan | — | — | — | — | — | 2 | |
| Liposomal irinotecan | — | — | — | — | — | 1 | |
| docetaxel | — | — | — | — | — | 1 | |
| cetuximab | — | — | — | — | 3 | ||
| RMC-9805 | — | — | — | — | 3 | ||
| RMC-6291 | — | — | — | — | 2 | ||
| Elironrasib | — | — | — | — | — | 2 | |
| mFOLFOX6 regimen | — | — | — | — | — | 1 | |
| bevacizumab | — | — | — | — | — | 1 | |
| mFOLFIRINOX regimen | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Pemetrexed | — | — | — | — | — | 1 | |
| Ivonescimab | — | — | — | — | — | 1 | |
| Carboplatin/Cisplatin + Pemetrexed | — | — | — | — | — | 1 | |
| RMC-5127 | — | — | — | — | — | 1 |
Next readouts
- 2026-06
- 2026-12-31
- 2027-03-31
- 2027-05-15
- 2027-05-31
- 2027-06
- 2027-12-01
- 2028-04
- 2028-06
- 2028-12
Top conditions
- PDAC7
- Pancreatic Cancer6
- PDAC - Pancreatic Ductal Adenocarcinoma5
- Pancreatic Ductal Adenocarcinoma (PDAC)5
- Colorectal Cancer (CRC)5
- Pancreatic Adenocarcinoma4
- Non-small Cell Lung Cancer (NSCLC)4
- Advanced Solid Tumors4
Frequently asked questions about Revolution Medicines, Inc.
- How many clinical trials does Revolution Medicines, Inc. have on ClinicalTrials.gov?
- Revolution Medicines, Inc. is listed as the lead sponsor on 18 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Revolution Medicines, Inc.'s trials are in Phase 3?
- 5 of Revolution Medicines, Inc.'s trials are in Phase 3, spread across 25 active drug programs.
- What therapeutic areas does Revolution Medicines, Inc. focus on?
- Revolution Medicines, Inc.'s most-studied conditions on ClinicalTrials.gov are PDAC, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC).
- When are Revolution Medicines, Inc.'s next clinical trial readouts?
- Revolution Medicines, Inc. has 10 upcoming primary-completion readouts tracked here; the soonest is “Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)”, expected around 2026-06.